Corcept resubmits NDA for relacorilant to treat Cushing's syndrome

June 17, 2026 4:28 PM

Corcept Therapeutics (NASDAQ: CORT) has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found